FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317356376> ?p ?o ?g. }

• W4317356376 abstract "Understanding the durability of the protection conferred by SARS-CoV-2 infection and vaccination is of utmost importance to guide COVID-19 mitigation policies worldwide. In November, 2021, before the emergence of the omicron (B.1.1.529) variant, an estimated 3·8 billion people (44% of the global population) had been infected by SARS-CoV-2.1COVID-19 Cumulative Infection CollaboratorsEstimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.Lancet. 2022; 399: 2351-2380Summary Full Text Full Text PDF PubMed Scopus (34) Google Scholar This number is likely to have exponentially increased with the spread of the omicron variant, the most transmissible SARS-CoV-2 variant to date, suggesting that most of the global population has now already experienced SARS-CoV-2 infection at least once. As with previous infections, vaccines induce a memory response and protection against COVID-19, and the combination of SARS-CoV-2 infection and vaccination (hybrid immunity) offers the highest rate of protection.2Crotty S Hybrid immunity.Science. 2021; 372: 1392-1393Crossref Scopus (105) Google Scholar However, the durability of this protection against reinfection and severe disease remains undefined. In The Lancet Infectious Diseases, Niklas Bobrovitz and colleagues3Bobrovitz N Ware H Ma X et al.Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.Lancet Infect Dis. 2023; (published online Jan 18.)https://doi.org/10.1016/S1473-3099(22)00801-5Summary Full Text Full Text PDF Google Scholar present the results of a well-conducted systematic review and meta-analysis investigating the long-term benefit of SARS-CoV-2 vaccines in individuals who have developed hybrid immunity. The authors observed ephemeral protection against reinfection after booster vaccination (46·5% [36·0–57·3] at 6 months) or previous infection (24·7% [95% CI 16·4–35·5] at 12 months) but sustained high levels of protection against hospital admission or severe disease 6–12 months after the last exposure to SARS-CoV-2 antigens (97·4% [95% CI 91·4–99·2] with primary series vaccination at 12 months and 95·3% [81·9–98·9] with the first booster vaccination at 6 months). The magnitude and durability of protection was particularly high for those with hybrid immunity compared to those with previous infection alone, reinforcing the importance of vaccination despite previous infection in protecting against severe disease due to the omicron variant. There were two important findings about the primary series versus the booster dose in cases of previous infection: the primary series offered a high rate of protection (>90%) against severe disease, without imparting additional protection after booster vaccination; and both the primary series and booster vaccination offered short-term protection against reinfection. These findings align with the preserved cellular immune response despite the decrease in the humoral response to omicron subvariants.4Jacobsen H Cobos Jiménez V Sitaras I et al.Post-vaccination T cell immunity to omicron.Front Immunol. 2022; 13944713Crossref Scopus (1) Google Scholar, 5Cao Y Song W Wang L et al.Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.Cell Host Microbe. 2022; 30: 1527-1539Summary Full Text Full Text PDF PubMed Scopus (9) Google Scholar Nonetheless, these findings should be interpreted with caution since the conclusions cannot be extrapolated to specific groups at increased risk of developing severe disease, such as older and immunosuppressed people, who were not analysed in this study. Despite this limitation, these findings have important implications for public health policies. Reducing infection has been the focus of first-generation vaccines against SARS-CoV-2 and has been investigated from the first clinical trials to most effectiveness studies. After the first 2 years of massive vaccination campaigns worldwide and almost 1 year of omicron subvariants causing high rates of infection worldwide, Bobrovitz and colleagues3Bobrovitz N Ware H Ma X et al.Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.Lancet Infect Dis. 2023; (published online Jan 18.)https://doi.org/10.1016/S1473-3099(22)00801-5Summary Full Text Full Text PDF Google Scholar clearly demonstrate that the focus of first-generation vaccines should be prevention of severe disease. For this purpose, a first-generation vaccine is still an excellent option when offered as a primary series in areas with a high rate of previous infection, or with boosters, if a low infection rate has been observed. Several countries still face vaccine shortages, and the benefit of offering multiple booster doses should be discussed in light of the findings of the present study.3Bobrovitz N Ware H Ma X et al.Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.Lancet Infect Dis. 2023; (published online Jan 18.)https://doi.org/10.1016/S1473-3099(22)00801-5Summary Full Text Full Text PDF Google Scholar Even though nearly 70% of the world's population has received at least one SARS-CoV-2 vaccine dose, the distribution of vaccine coverage remains unequal. North America has vaccinated approximately 76% of its population with one dose, while Africa has only vaccinated 32%.6Mathieu E Ritchie H Rodés-Guirao L et al.Coronavirus pandemic (COVID-19). Our World Data.https://ourworldindata.org/coronavirusDate: March 5, 2020Date accessed: December 12, 2022Google Scholar High-income countries administered almost five times more doses than low-income countries for the primary series and more than 20 times more booster doses.6Mathieu E Ritchie H Rodés-Guirao L et al.Coronavirus pandemic (COVID-19). Our World Data.https://ourworldindata.org/coronavirusDate: March 5, 2020Date accessed: December 12, 2022Google Scholar Coverage can be improved even in countries with high availability of vaccines. For example, in the USA only 69% of the population has completed the primary series vaccination.6Mathieu E Ritchie H Rodés-Guirao L et al.Coronavirus pandemic (COVID-19). Our World Data.https://ourworldindata.org/coronavirusDate: March 5, 2020Date accessed: December 12, 2022Google Scholar This inequality of distribution between low-income and high-income countries and the relatively high refusal to receive vaccines in high-income countries still need to be addressed to achieve higher protection against hospital admission and death due to COVID-19. These strategies could include more equitable distribution of vaccines within countries and improved communication about the protection offered by hybrid immunity. We are currently facing a new wave of omicron subvariants. While waiting for data about the effectiveness of bivalent and other next-generation vaccines, the gold standards against COVID-19 remain both non-pharmacological strategies to prevent SARS-CoV-2 infection and vaccination to avoid severe disease. VSB and MB-N are employees of Fiocruz, a federal public institution that manufactures the ChAdOx1 (Oxford–AstraZeneca) vaccine in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health in Brazil for public health use. TC-S declares no competing interests. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regressionAll estimates of protection waned within months against reinfection but remained high and sustained for hospital admission or severe disease. Individuals with hybrid immunity had the highest magnitude and durability of protection, and as a result might be able to extend the period before booster vaccinations are needed compared to individuals who have never been infected. Full-Text PDF Open Access" @default.
• W4317356376 created "2023-01-19" @default.
• W4317356376 creator A5010814212 @default.
• W4317356376 creator A5053471036 @default.
• W4317356376 creator A5084545243 @default.
• W4317356376 date "2023-01-01" @default.
• W4317356376 modified "2023-09-30" @default.
• W4317356376 title "The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era" @default.
• W4317356376 cites W4206684097 @default.
• W4317356376 cites W4223443877 @default.
• W4317356376 cites W4287921924 @default.
• W4317356376 cites W4301394219 @default.
• W4317356376 cites W4317356311 @default.
• W4317356376 doi "https://doi.org/10.1016/s1473-3099(22)00880-5" @default.
• W4317356376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36681085" @default.
• W4317356376 hasPublicationYear "2023" @default.
• W4317356376 type Work @default.
• W4317356376 citedByCount "1" @default.
• W4317356376 countsByYear W43173563762023 @default.
• W4317356376 crossrefType "journal-article" @default.
• W4317356376 hasAuthorship W4317356376A5010814212 @default.
• W4317356376 hasAuthorship W4317356376A5053471036 @default.
• W4317356376 hasAuthorship W4317356376A5084545243 @default.
• W4317356376 hasBestOaLocation W43173563761 @default.
• W4317356376 hasConcept C116675565 @default.
• W4317356376 hasConcept C126322002 @default.
• W4317356376 hasConcept C159047783 @default.
• W4317356376 hasConcept C22070199 @default.
• W4317356376 hasConcept C2778137277 @default.
• W4317356376 hasConcept C2779134260 @default.
• W4317356376 hasConcept C3006700255 @default.
• W4317356376 hasConcept C3007834351 @default.
• W4317356376 hasConcept C3008058167 @default.
• W4317356376 hasConcept C524204448 @default.
• W4317356376 hasConcept C71924100 @default.
• W4317356376 hasConceptScore W4317356376C116675565 @default.
• W4317356376 hasConceptScore W4317356376C126322002 @default.
• W4317356376 hasConceptScore W4317356376C159047783 @default.
• W4317356376 hasConceptScore W4317356376C22070199 @default.
• W4317356376 hasConceptScore W4317356376C2778137277 @default.
• W4317356376 hasConceptScore W4317356376C2779134260 @default.
• W4317356376 hasConceptScore W4317356376C3006700255 @default.
• W4317356376 hasConceptScore W4317356376C3007834351 @default.
• W4317356376 hasConceptScore W4317356376C3008058167 @default.
• W4317356376 hasConceptScore W4317356376C524204448 @default.
• W4317356376 hasConceptScore W4317356376C71924100 @default.
• W4317356376 hasLocation W43173563761 @default.
• W4317356376 hasLocation W43173563762 @default.
• W4317356376 hasLocation W43173563763 @default.
• W4317356376 hasOpenAccess W4317356376 @default.
• W4317356376 hasPrimaryLocation W43173563761 @default.
• W4317356376 hasRelatedWork W3005417802 @default.
• W4317356376 hasRelatedWork W3007868867 @default.
• W4317356376 hasRelatedWork W3009669391 @default.
• W4317356376 hasRelatedWork W3020699490 @default.
• W4317356376 hasRelatedWork W3036314732 @default.
• W4317356376 hasRelatedWork W3043486364 @default.
• W4317356376 hasRelatedWork W3084498529 @default.
• W4317356376 hasRelatedWork W3090578646 @default.
• W4317356376 hasRelatedWork W4210401150 @default.
• W4317356376 hasRelatedWork W3127156785 @default.
• W4317356376 isParatext "false" @default.
• W4317356376 isRetracted "false" @default.
• W4317356376 workType "article" @default.